Fat Body Mass and Vertebral Fracture Progression in Women With Breast Cancer.

ABSTRACT:

Importance

Women with early breast cancer (EBC) exposed to aromatase inhibitors (AIs) may experience fragility fractures despite treatment with bone-active drugs. Risk factors for fractures in patients receiving AIs and denosumab have not been explored to date.

Objectives

To evaluate whether an association exists between dual x-ray absorptiometry (DXA)-measured fat body mass (FBM) and vertebral fracture (VF) progression in postmenopausal women with EBC undergoing adjuvant therapy with AIs in combination with denosumab and to examine whether VF was associated with common risk factors for bone fracture and parameters of body composition other than FBM.

Design, setting, and participants

For this prospective, single-center, cohort study, 237 patients with EBC who were und

SUBMITTER: Cosentini D 

PROVIDER: S-EPMC10782249 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature